Immix Biopharma, Inc. 8-K

What Happened

• Immix Biopharma, Inc. announced on May 21, 2026 that it entered into an underwriting agreement with Morgan Stanley & Co. LLC (as representative) to sell 16,778,524 shares of common stock at $8.94 per share. The offering is expected to close on May 22, 2026, subject to customary closing conditions.
• The company estimates net proceeds from the offering, after underwriting discounts, commissions and estimated expenses, to be approximately $140.65 million. The offering is being made pursuant to a shelf registration statement declared effective by the SEC on January 22, 2026 (File No. 333-292665).

Key Details

• Shares offered: 16,778,524 common shares.
• Public offering price: $8.94 per share (gross proceeds ≈ $150.0 million).
• Estimated net proceeds to Immix: approximately $140.65 million.
• Underwriter representative: Morgan Stanley & Co. LLC; expected closing date: May 22, 2026. Legal opinion from Blank Rome LLP and a press release announcing pricing were filed as exhibits to the 8-K.

Why It Matters

• This transaction will raise substantial capital for Immix (net ≈ $140.7M), which can affect the company’s cash runway and ability to fund operations or development programs.
• The offering will increase the number of outstanding shares and dilute existing shareholders proportionally.
• The 8-K includes standard forward-looking cautions; the filing does not provide a detailed breakdown of how the net proceeds will be used.